The Biotech Year in Review
641243
A look at the highlights and lowlights of 2007.
196733
The world of science has been busy all through 2004. The probing eye looked in all directions. It looked at the skies, at the ground beneath our feet, at the wings of a butterfly and at the molecules of water.
673248
The biotechnology company earned $186.1 million during the second quarter, citing strong sales of two drugs.
267800
Last week's disclosure that former House Speaker Thomas Finneran will run the Massachusetts Biotechnology Council was just the latest sign that life sciences is a key industry in Boston.
683806
The biotech company reported net income of $833 million, or 71 cents per share, for the latest quarter.
740585
The beginning of the year is traditionally a time to look back, and, for the brave of heart, to make a few predictions looking forward.  Lacking the requisite bravery, I'll just quote something that the Economist wrote recently: Rejoice: the embrace of âopennessâ by firms that have grown fat on closed, proprietary technology is something weâll see more of in 2008.  Now, had this "fearless prediction" been made a year ago, I would have been impressed, because 2007 has turned out to be the year when everyone, it seems, wants to be open. read more
494020
Big opportunities await patient investors in nanotech, cleantech, and robotics.
301149
Cambridge Antibody Technology&#39;s (Nasdaq: CATG) legal victory over Abbott Laboratories (NYSE: ABT) shows that a biotech David can triumph over a pharmaceutical Goliath.
447760
Hard-earned tips from a biotech investor.
130561
The biotechnology revolution is shaking up the pet world.
86874
If you added all the biotech activity that industry executives and local officials across the country have forecast for the next decade, my guess is the industry would be roughly the size of the Chinese economy.
28653
Biotech and high technology, two key Massachusetts industries, are often seen as allies -- innovation-driven businesses that depend on a highly educated workforce. But this week they're on opposite sides of a fight playing out in Washington: How to overhaul the nation's patent system.
227527
A look at the events and highlights slated for the upcoming year.
172265
Charly Travers offers advice on withstanding the volatility of the biotech sector.
307489
Genzyme Corp. chief executive Henri A. Termeer's conference call with Wall Street on May 8, 2003, quickly turned ugly. Analysts peppered him with questions about the Cambridge biotech company's plan to buy back shares of its biosurgery division. The price, they said, was far too low.
538684
Technology Review presents its annual list of the 10 most exciting technologies.
321553
Blockbuster products help the biotech firm continue its stellar performance.